trending Market Intelligence /marketintelligence/en/news-insights/trending/4MtvUa2gfCkp2-FWjVkkOg2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Depomed to lose some revenue as a result of Hurricane Maria

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Depomed to lose some revenue as a result of Hurricane Maria

Depomed Inc. said it would lose about $2 million to $3 million in third-quarter Nucynta-related revenues as a result of damage caused by Hurricane Maria.

The opioid painkiller is produced in Puerto Rico by a third-party manufacturing partner. According to the most recent assessment, the facility that produces the drug sustained minor damage, and site leaders are working to return the facility to full operation.

The company expects a further negative impact of less than $10 million in fourth-quarter Nucynta revenues as a result of the ongoing disruption to manufacturing operations.

The disruption will not impact the supply of Gralise, which is also produced in Puerto Rico.

Nucynta generated $281.2 million in revenue during the full year ended Dec. 31, 2016. For the six months ended June 30, 2017, the drug generated $124.6 million in sales.